Abstract
We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months.
| Original language | English (US) |
|---|---|
| Article number | 101714 |
| Journal | Urology Case Reports |
| Volume | 38 |
| DOIs | |
| State | Published - Sep 2021 |
All Science Journal Classification (ASJC) codes
- Urology
Fingerprint
Dive into the research topics of 'Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver